#Jim fink stocks how to#
However, in a unique one-time event, you can join Keith for a special Catalyst Calendar summit where he will show you where you can learn about these opportunities and and how to cash in on these flash gains.īy registering for this special one-time event, you can take part in one of the biggest trading opportunities of the year. The information about these catalysts isn’t readily available. It isn't easy to capture these fast-moving paydays. One of Your Best Trading Opportunities of the Year A 25% winner on Allied Healthcare Products in just five days.A one-week gain of 60% on Durect Corporation.A two-week 225% payday on Intra-Cellular Therapies.Take for instance some recent wins from my colleague and market analyst Keith Kohl: Some of these time frames can be extremely short, and if you have stakes in the even more explosive opportunities, you can make some serious cash. The point is if you know how to spot the catalyst before it ignites a surge, you can make a pretty profit in a relatively short time frame. (NASDAQ: AMGN) at 46%, Ocular Therapeutix (NASDAQ: OCUL) at 92%, or even the Ark Genomic Revolution ETF (ARKG), which is led by future tech investment guru Cathy Wood and, despite pullback in all Ark ETFs recently, is still up over 146% over the past two years as of this past Tuesday. I could go on with the gains folks like you can score in the biotech and medtech sectors, such as Amgen Inc. Today, INSP trades around $180, representing an open gain of over 399% so far. The product was revolutionary and only just recently approved - the perfect catalyst for gains.
#Jim fink stocks full#
When activated during sleep, the device opens the user's airways, allowing for a full night's sleep. The product eliminates the need for clunky masks and is monitored via handheld remote. The company had just IPO’d a few months prior, and the catalyst for big gains was that it had the only FDA-approved internal sleep apnea device on the market. Just a month later, on June 27, 2018, I suggested my followers take a swing on Inspire Medical Systems (NYSE: INSP) at a price of $36.32.
#Jim fink stocks free#
You'll also get our free report, “The (Safest) Way to Invest in Biotech.” That catalyst powered MRK shares to some nice gains and quick profits for those who took my advice at the time.
#Jim fink stocks trial#
Trial data was very promising, which was very important because Keytruda had the potential to treat numerous different forms of cancer. In 2018, MRK was close to releasing a new cancer drug called Keytruda. By late December 2019, shares were trading just shy of $90. On May 23, 2018, I recommended Merck & Co. It’s important to know that these opportunities are not random events. The chart above covers the following five months as the market got wind of the drug’s efficacy and effectiveness.Įven despite a massive sell-off as the herd took profits late in 2018, shares today are near new all-time highs at $139. More specifically, this therapy represented the first FDA-approved regimen for frontline treatment of Stage 3 and 4 Hodgkin's lymphoma in over 40 years. The catalyst back in 2018 was an FDA approval on its Adcetris therapy for the treatment of Hodgkin's lymphoma. By the end of the year, the stock had nearly doubled in value after rising over $80 per share.
On April 5, 2018, I recommended a lesser-known biotech formerly named Seattle Genetics, now named Seagen Inc. This is because medtech and biotech stocks are catalyst-driven. The second thing I learned is that over the course of time, the medtech and biotech industries offer investors the most chances at triple-digit gains in any given month. The first is that the success of an individual medical technology (medtech) or biotechnology (biotech) company isn’t directly tied to the greater cyclical forces that often affect other stocks. In doing so, I learned two very important things.
Watch the recording of the event here.ĭuring my analyst coverage in 2018, I covered the biotech sector very closely. *Editor’s Note: Our Catalyst Calendar event is available to view right now.
0 kommentar(er)
